Miller PG, Sperling AS, Brea EJ, et al. Clonal Hematopoiesis in Patients Receiving Chimeric Antigen Receptor T-Cell Therapy. Blood Advances. 2021; 5 (15): 2982 (doi: 10.1182/bloodadvances.2021004554).
New research suggests that clonal hematopoiesis of indeterminate potential (CHIP) affects chimeric antigen receptor (CAR) T-cell biology and clinical results in patients with non-Hodgkin lymphoma (NHL) and multiple myeloma (MM), but it is not associated with lower survival. The study included 154 patients with NHL or MM who were receiving CAR T-cell therapy. CHIP was detected in 48% of the patients. In individuals younger than age 60 years, the condition was associated with higher rates of complete response and cytokine release syndrome severity. Regardless of age, there was no association observed between CHIP and differences in progression-free or overall survival. Based on their findings, the study authors assert that CHIP should not exclude patients from receiving CAR T-cell therapy.
Tags: CAR-T, Abstracts, cell therapy, outcome, newsletter, T-Cell, CART, CHIP, impact